Cagrilintide + semaglutide (CagriSema)
REDEFINE 1 reported -20.4% mean weight change versus -3.0% with placebo at 68 weeks in obesity.
Exact-combination evidence
Multiple randomized Phase II/III combination trials
REDEFINE 1 reported -20.4% mean weight change versus -3.0% with placebo at 68 weeks in obesity. In 2026, REIMAGINE 2 found the 2.4/2.4 mg combination statistically superior to semaglutide 2.4 mg for HbA1c in type 2 diabetes. A published erratum for REIMAGINE 2 remains part of the evidence record, and combination results are kept separate from cagrilintide monotherapy.
Human combination evidence
Yes — REDEFINE 1/2 and REIMAGINE programmes
Combination safety
Yes — trial safety datasets
Component evidence and direct combination evidence are kept separate. Study doses or regimens, where mentioned, describe the cited research only and are not recommendations for personal use.